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What You Need to KnowBackground and ContextThe first year of life is a critical time for development of the gut microbiome and it is unknown whether neonatal or postnatal events (for up to one year and longer) could impact the risk for developing IBD.New FindingsA maternal diagnosis of IBD was the strongest risk factor for the offspring developing IBD. Other risk factors included infection in the first year of life and being born into a family of higher socioeconomic standard.LimitationsThis was an administrative database study and it was not clear whether the risk posed by infections were from infections per se or the antibiotics used to treat them, among other variables.ImpactHealth providers and parents need to be more circumspect about antibiotic use especially for young children. Further research should be undertaken to study breastfeeding and diet in the first year of life to determine their impact on IBD risk

It is unknown what triggers the development of inflammatory bowel disease (IBD). However, there is emerging evidence of important dysbiotic changes in the gut microbiome in persons with IBD, such as reduced diversity and alterations in certain species.[@bib1] A variety of factors can change the gut microbiome, such as antibiotic ingestion or dietary changes. However, the permanence of the gut microbiome changes may be dependent on the timing and/or duration of what factor is introduced. The gut microbiome undergoes the most change from birth until 1--2 years of age, when the microbiota composition stabilizes.[@bib2], [@bib3], [@bib4] Hence, events that promote alterations in the composition of the gut microbiome in the first year of life may have important effects on its more permanent composition. This, in turn, may impact on the ultimate development of IBD. Infections that impact on the gut microbiome and antibiotic use in the first year of life through their effects on the gut microbiome may, therefore, impact on the ultimate development of IBD.

Therefore, we aimed to determine whether there was an increased risk of IBD among persons who had critical events at birth or within the first year of life, which would be expected to lead to alterations in the gut microbiome. Further, we explored whether these events affected risk for IBD differentially at different ages of IBD onset.

Methods {#sec1}
=======

The University of Manitoba IBD Epidemiology Database contains records on all Manitobans diagnosed with IBD between 1984 and 2010. Each individual is identified by a unique personal health identification through which all health system contacts can be tracked dating back to 1984. In 1995, we validated an administrative definition of IBD based on frequency of health system contacts.[@bib5] We identified all persons with IBD and created a matched cohort of controls, matching 10 controls without IBD by age, sex, and area of residence to each IBD case. Our administrative definition of IBD allowed updating our database with new cases on an ongoing basis. Starting in 1970, 6-digit family health registration numbers, shared by a mother and all of her offspring, have been used in Manitoba and allow for the accurate linkage of the health care utilization profiles of mothers with their children.[@bib6] Information on diagnoses associated with health care visits or hospitalizations during the neonatal and postnatal periods was available from 1970 to 2010. All hospitalizations and discharge diagnoses (up to 20 by International Classification of Disease, 9^th^ Revision, Clinical Modification codes to 2004 and up to 25 by International Classification of Disease, 10^th^ Revision, Clinical Modification codes after 2004) and outpatient contacts (by International Classification of Disease, 9^th^ Revision, Clinical Modification codes) were tracked. The Medical Records Department of the Children's Hospital of Winnipeg provided all International Classification of Disease, 10^th^ Revision codes identified as the number one discharge abstract diagnosis for the hospitalizations of all children under age 3 years in the years 2013--2016. This allowed the casting of a wide net for possible infections or gastrointestinal illnesses associated with early life hospitalization. We assessed for 26 different categories of infection, 4 categories of gastrointestinal illness, failure to thrive, and for hospital readmission. The types of infections and gastrointestinal illnesses are listed in [Supplementary Table 1](#tblS1){ref-type="table"}. The infections included those likely to require antibiotic therapy and also viral infections; it was considered that, if a child was sufficiently ill to be admitted to hospital, even if the discharge diagnosis was that of a viral infection, at some point the child may have received antibiotic therapy. However, we also included a separate analysis excluding what were diagnosed as viral infections. We assessed for the occurrence of those events within the first year of life. We also assessed for those events within the first 3 years of life. Inpatient and outpatient diagnoses were combined in each category to increase the power to determine if any diagnoses with these conditions were associated with a later diagnosis of IBD. We assessed for maternal diagnosis of IBD and we assessed for mode of delivery (cesarean section vs vaginal delivery). Considering that some diagnoses of IBD could actually be cases of immunodeficiency syndromes and that persons who are immunodeficient would incur more infections and antibiotic use, we compared the rates for immunodeficiency syndromes among persons with IBD and controls by International Classification of Disease, 9^th^ Revision, Clinical Modification code 279 and by the following International Classification of Disease, 10^th^ Revision, Canada codes including immunodeficiency with predominantly antibody defects (D80), combined immunodeficiencies (D81), immunodeficiency associated with other major defects (D82), common variable immunodeficiency (D83) and other immunodeficiencies (D84). From 1979 onward, data were available on gestational age, Apgar score, neonatal intensive care unit admission, and birth weight. We also assessed rural vs urban residence and family socioeconomic status by quintile at birth. To assess socioeconomic status, we used the median household income quintile for the area of residence at the time of birth identified by the subjects' 6-digit postal code at the time of birth.[@bib7]

Outcomes and Analysis {#sec1.1}
---------------------

We compared incident rate of infections, gastrointestinal illnesses, and failure to thrive identified from outpatient visits and on hospitalizations (from the hospital discharge abstracts) between IBD cases and their matched controls, as well as between IBD cases and their siblings. We also analyzed neonatal events. For all of the neonatal events as well as events within the first year of life, we assessed for subsequent development of IBD at any age, development of IBD before age 10 years and development of IBD before age 20 years. We assessed for all diagnoses of IBD and then separately for diagnoses of Crohn's disease and for ulcerative colitis. Comparisons used Fisher's exact test for each category of clinical disease assessed, for socioeconomic status at birth, for rural vs urban residence at birth and for neonatal parameters (mode of delivery, gestational age, birth weight, Apgar score, and neonatal intensive care unit admission). Conditional logistic regression models estimated the odds of developing IBD compared to either matched controls or siblings, and odds ratios (ORs) with 95% confidence intervals (CI) are reported for all individuals available from 1979 so that all variables could be included. We conducted a separate conditional logistic regression model for all individuals available since 1970, excluding the neonatal events available only since 1979 in the model. We repeated these analyses comparing IBD cases with their unaffected siblings.

This study was approved by the University of Manitoba Health Research Ethics Board, the Manitoba Health Information Privacy Committee and the Manitoba Centre for Health Policy Review Committee.

Results {#sec2}
=======

We were able to link the administrative health records of 1671 IBD cases, 1740 siblings, and 10,488 matched controls to their mothers dating back to 1970. The median age of the IBD cohort was 20.0 years (range, 1.0--39.0 years; 25^th^ percentile, 16; 75^th^ percentile, 25). A total of 6824 individuals (n = 825 for IBD cases and n = 5999 for controls) were available to examine all events dating back to 1979. The median age for this cohort was 17.0 years (range 1--30.0; 25^th^ percentile, 13; 75^th^ percentile, 21). This cohort including data dating back to 1979 was used for the following analyses. Among IBD cases, 97 were diagnosed before age 10 years, 499 were diagnosed between ages 10--20 years, and 229 were diagnosed after age 20 years. The strongest predictor for development of IBD in all models was maternal history of IBD (OR, 4.53; 95% CI, 3.08--6.67 in the model including all neonatal and first year of life events). The model assessing all neonatal events and events in the first year of life found that being in the highest or the second highest socioeconomic quintile at birth vs the lowest (OR, 1.35; 95% CI, 1.01--1.79 and OR, 1.37; 95% CI, 1.06--1.77, respectively) and infections within the first year of life were associated with later development of IBD at any age (OR, 1.39; 95% CI, 1.09--1.79) ([Table 1](#tbl1){ref-type="table"} ). When assessing Crohn's disease (n = 482) separately from ulcerative colitis (n = 343), maternal history of IBD was strongly predictive for both diseases, and having an infection in the first year life trended toward being predictive but did not reach statistical significance in either disease ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} ). Being in a higher socioeconomic status at birth compared to the lowest quintile was predictive of developing ulcerative colitis for all 4 socioeconomic quintiles above the lowest. Assessing neonatal events only, for later development of IBD, the only predictors of later development of IBD were being in the highest vs lowest socioeconomic status by quintile (OR, 1.35; 95% CI, 1.01--1.79) or being in the second highest versus lowest socioeconomic quintile (OR, 1.37; 95% CI, 1.06-1.77).Table 1Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Inflammatory Bowel Disease, at Any Age Among All Persons With Inflammatory Bowel Disease Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* value[IBD]{.ul}*P* valueCase[a](#tbl1fna){ref-type="table-fn"} (n = 825)Control[a](#tbl1fna){ref-type="table-fn"} (n = 5999)Infection year 1Yes vs no1.391.09, 1.79.0190.387.6.03Socioeconomic status Q1------------14.7917.57.05 NFNF vs Q10.760.37, 1.56.451.11.8--- Q2Q2 vs Q11.311.02, 1.68.3623.5221.72--- Q3Q3 vs Q11.090.84, 1.42.5219.3921.47--- Q4Q4 vs Q11.371.06, 1.77.0224.3621.94--- Q5Q5 vs Q11.351.01, 1.79.0416.8515.5---GeographyRural vs urban0.910.72, 1.15.4538.937.3.18Apgar 1 min7+ vs \<71.090.86, 1.39.4688.12[b](#tbl1fnb){ref-type="table-fn"}86.73.2Apgar 5 min7+ vs \<71.070.49, 2.33.8799.03[b](#tbl1fnb){ref-type="table-fn"}98.8.56ICU admissionNo vs yes1.060.63, 1.77.8397.697.23.57Gestational age---1.0040.95, 1.06.8839.439.4.88Birth weight---1.0001.000, 1.000.793451ˆ3444[c](#tbl1fnc){ref-type="table-fn"}.76Readmitted in yr 1No vs yes1.210.94, .56.1488.3686.23.09Cesarean sectionYes vs no1.060.86, 1.32.5714.1814.07.93Maternal IBDYes vs no4.533.08, 6.67\<.0015.451.25\<.001Hospitalized for GIYes vs no0.790.46, 1.36.392.182.90.24[^1][^2][^3][^4]Table 2Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Crohn's Disease, at Any Age Among All Persons With Crohn's Disease Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs no1.370.99, 1.89.06Socioeconomic status Q1NF vs Q10.410.12, 1.39.15 Q2Q2 vs Q11.110.81, 1.53.51 Q3Q3 vs Q10.860.61, 1.20.37 Q4Q4 vs Q11.210.87, 1.69.25 Q5Q5 vs Q11.120.78, 1.62.54GeographyRural vs urban0.910.67, 1.24.56Apgar 1 min7+ vs \<71.421.02, 1.96.04Apgar 5 min7+ vs \<71.330.38, 4.61.67ICU admissionNo vs yes0.910.49, 1.67.76Gestational age---1.010.94, 1.08.77Birth weight---1.0001.000, 1.000.96Readmitted in year 1No vs yes1.180.84, 1.65.34Cesarean sectionYes vs no0.940.71, 1.26.68Maternal IBDYes vs no5.983.72, 9.63\<.001Hospitalized for GI[a](#tbl2fna){ref-type="table-fn"}Yes vs no0.670.30, 1.51.34[^5][^6]Table 3Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Ulcerative Colitis, at Any Age Among All Persons With Ulcerative Colitis Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs No1.410.95, 2.08.09Socioeconomic status Q1NF vs Q11.200.48, 3.00.69 Q2Q2 vs Q11.611.07, 2.41.02 Q3Q3 vs Q11.510.996, 2.29.05 Q4Q4 vs Q11.631.08, 2.46.02 Q5Q5 vs Q11.711.09, 2.69.02GeographyRural vs urban0.910.64, 1.29.6Apgar 1 min7+ vs \<70.780.55, 1.11.17Apgar 5 min7+ vs \<71.040.37, 2.89.95ICU admissionNo vs yes1.310.48, 3.57.6Gestational age---0.990.91, 1.08.84Birth weight---1.0001.000, 1.000.61Readmitted in year 1No vs yes1.250.84, 1.84.27Cesarean sectionYes vs no1.220.89, 1.69.22Maternal IBDYes vs no2.711.34, 5.51.01Hospitalized for GI[a](#tbl3fna){ref-type="table-fn"}Yes vs no0.870.41, 1.86.73[^7][^8]

The predictors of being diagnosed with IBD under age 10 (n = 97 IBD cases and 748 controls) included maternal diagnosis of IBD (OR, 5.92; 95% CI, 1.76--19.98), having an infection in the first year of life (OR, 3.06; 95% CI, 1.07--8.78), and being born rural vs urban (OR, 2.54; 95% CI, 1.24--5.20) ([Table 4](#tbl4){ref-type="table"} ). The predictors of being diagnosed with IBD under age 20 years (n = 499 IBD cases and 4503 controls) included maternal diagnosis of IBD (OR, 4.95; 95% CI, 3.18--7.71), having an infection in the first year of life (OR, 1.63; 95% CI, 1.18--2.24), and being in the highest socioeconomic quintile compared with the lowest at birth (OR, 1.43; 95% CI, 1.02--2.00) ([Table 5](#tbl5){ref-type="table"} ). Maternal diagnosis of IBD was a significant predictor of developing Crohn's disease before age 10 years, but no variables significantly predicted development of ulcerative colitis before age 10 years ([Supplementary Tables 2](#tblS2){ref-type="table"} and [3](#tblS3){ref-type="table"}). Maternal diagnosis of IBD was a significant predictor of developing either Crohn's disease or ulcerative colitis before age 20 years and infection in the first year of life was a significant predictor of developing Crohn's disease but not ulcerative colitis before age 20 years ([Supplementary Tables 4](#tblS4){ref-type="table"} and [5](#tblS5){ref-type="table"}).Table 4Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Inflammatory Bowel Disease, Under Age 10 Years Among All Persons With Inflammatory Bowel Disease (n = 97) Compared to Controls (n = 748)EffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs no3.061.07, 8.78.04Socioeconomic status Q2Q2 vs Q11.980.93, 4.21.07 Q3Q3 vs Q11.440.64, 3.23.38 Q4Q4 vs Q11.680.75, 3.79.21 Q5Q5 vs Q11.290.53, 3.17.57GeographyRural vs urban2.541.24, 5.20.01Apgar 1 min7+ vs \<70.810.42, 1.54.51ICU admission---Gestational age---0.940.81, 1.09.44Birth weight---1.0001.000, 1.001.22Readmitted in year 1No vs yes0.920.49, 1.72.79Cesarean sectionYes vs no0.760.39, 1.48.41Maternal IBDYes vs no5.921.76, 19.98\<.01[^9]Table 5Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Inflammatory Bowel Disease, Under Age 20 Years Among All Persons With Inflammatory Bowel Disease (n = 591) Compared to Controls (n = 4491)EffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs no1.631.18, 2.24.003Socioeconomic status Q2Q2 vs Q11.461.09, 1.96.01 Q3Q3 vs Q11.110.81, 1.51.52 Q4Q4 vs Q11.371.01, 1.86.04 Q5Q5 vs Q11.431.02, 2.00.03GeographyRural vs urban0.980.73, 1.31.87Apgar 1 min7+ vs \<71.090.83, 1.43.55ICU admissionNo vs yes1.140.63, 2.05.67Gestational age---1.020.96, 1.08.57Birth weight---1.0001.000, 1.000.71Readmitted in year 1No vs yes1.130.84, 1.53.43Cesarean sectionYes vs no1.140.89, 1.45.29Maternal IBDYes vs no4.953.18, 7.71\<.001Hospitalized for GIYes vs no0.600.28, 1.27.18[^10]

In a model including data dating back to 1970 from all 1671 persons with IBD and 10,488 controls for mothers IBD status, socioeconomic status at birth, urban vs rural residence, and cesarean section were assessed. For persons with IBD diagnosed at any age, having a maternal IBD diagnosis (OR, 4.54; 95% CI, 3.40--6.06; *P* \< 0.001) and being born into the highest socioeconomic quintile vs the lowest (OR, 1.29; 95% CI, 1.05--1.59; *P* = 0.01) were predictive of developing IBD. Being born in rural area was protective against developing IBD (OR, 0.84; 95% CI, 0.72--0.99; *P* = 0.04).

We undertook an analysis assessing only hospitalizations for infections (excluding outpatient contacts for infection). This did not prove to be significantly predictive of developing IBD, although the sample size was likely too small. We also undertook an analysis of predictors of developing IBD excluding viral infections in the first year of life and in this model infections in the first year of life did not prove to be predictive of developing IBD. Only maternal diagnosis of IBD retained its significance as a predictor ([Supplementary Table 6](#tblS6){ref-type="table"}). Finally, we undertook an analysis of predictors of IBD, including infections in the first 3 years of life and we found that infections did not predict development of IBD. In this model only maternal diagnosis of IBD and being in the highest or second highest socioeconomic quintile compared to the lowest at birth predicted development of IBD ([Supplementary Table 7](#tblS7){ref-type="table"}).

Because infections in the first year of life was a strong predictor of developing IBD in several of our analyses, we explored the direct use of antibiotics where we could, and the diagnoses of immunodeficiency syndromes. From 1996 through 2010 (the years in which antibiotic data were available in our administrative data) within our cohort, there were only 33 individuals with IBD and 270 controls who were born after 1996. For this group of 303 individuals, the mean number of antibiotic prescriptions in the first 10 years of life was 8.97 (95% CI, 6.44--11.50) among persons with IBD compared with a mean of 7.59 (95% CI, 6.63--8.55) among controls (*P* = .34 for the difference between IBD cases and controls). We modeled antibiotic users, defined by actual antibiotic prescriptions in the first year of life; socioeconomic status at birth; and rural vs urban residence at birth, and there was a trend for antibiotic prescription in the first year of life predicting later IBD diagnosis; however, it was not statistically significant (OR, 1.66; 95% CI, 0.74--3.74; *P* = .21).

In assessing for immunodeficiency disorders at any time in life, we found them to be diagnosed in 34 of 825 (4.1%) of IBD cases and in 220 of 5999 (3.67%) controls (*P* = .49). Hence, neither overall childhood antibiotic use nor immunodeficiency disorder was associated with a diagnosis of IBD.

Unaffected sibling comparisons showed no predictors of developing IBD at any age ([Table 6](#tbl6){ref-type="table"} ). Having gastrointestinal infections, gastrointestinal disease, or abdominal pain in the first year of life did not increase the risk for developing IBD.Table 6Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Inflammatory Bowel Disease, Among All Persons With Inflammatory Bowel Disease (n = 827) Compared to Sibling Controls (n = 994)EffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 11 vs1.220.90, 1.66.19 Q1NF vs Q11.830.18, 18.73.61 Q2Q2 vs Q11.560.78, 3.13.21 Q3Q3 vs Q11.370.64, 2.95.42 Q4Q4 vs Q11.760.81, 3.81.15 Q5Q5 vs Q11.060.43, 2.61.89SexMale vs female0.950.74, 1.22.71Age at diagnosis[a](#tbl6fna){ref-type="table-fn"}---1.281.22, 1.34\<.001GeographyRural vs urban0.530.24, 1.19.13Apgar 1 min7+ vs \<71.330.90, 1.97.16Readmission 1 yNo vs Yes1.270.65, 2.45.48Cesarean sectionYes vs No1.210.66, 2.24.53[^11][^12]

Discussion {#sec3}
==========

We found that the strongest and most consistent predictor of developing IBD was having a mother with a diagnosis of IBD. This might reflect either an important genetic effect or an important environmental effect or a combination of both. Children share a close environment with their mothers, especially in their developing years, and it has been shown that the gut microbiome of children increasingly mirrors that of their parents' gut microbiome from the second through the sixth month of life.[@bib8] We also found that persons with IBD were significantly more likely to be born into higher socioeconomic status families. The association between higher socioeconomic status and IBD may be reflective of the hygiene hypothesis, which posits that a cleaner lifestyle is associated with an increase in chronic immune diseases.[@bib9], [@bib10], [@bib11] This lifestyle may involve less risk for childhood infections, cleaner water sources and toilet facilities, and less home crowding. It also may reflect greater attention to health care. Being born into a higher socioeconomic lifestyle may impact on duration of breastfeeding and timing and types of foods that are introduced in the first year of life.[@bib12] Because higher socioeconomic status at birth poses a risk for developing IBD, and prolonged breastfeeding may be protective against developing IBD, then further research will need to tease out which has a greater impact on ultimate development of IBD.[@bib12] We have previously shown that among persons ultimately diagnosed with IBD, compared to controls there was no difference in likelihood of initiating breastfeeding just after delivery,[@bib13] however, studies are needed to ascertain whether the duration of breastfeeding, as well as the exclusivity of breastfeeding (to what extent or at what age formula or table food was introduced) impact on the development of IBD. This will require a prospective study. Being born in rural vs urban settings was predictive of developing IBD (more specifically Crohn's disease) among children under age 10 years, but not for IBD diagnoses at other ages. This contrasts with a Canada-wide report that suggested that rural residence was protective against developing IBD mostly among children who lived rurally under age 5 years, but found a wide variation among provinces.[@bib14] When we assessed a larger sample size excluding neonatal events and assessing maternal and demographic factors with data going back to 1970 (n = 1670 for persons with IBD), being born rural was protective against developing IBD. Further research is required to determine what aspects of a higher family socioeconomic status at birth and family life in general contribute to an increased risk of chronic immune diseases, especially IBD.

Finally, infections in the first year of life were predictive of development of IBD at any age and with the strongest association for infections in the first year of life and development of IBD before age 10 years. We, and others, have previously shown that antibiotics early in life,[@bib15], [@bib16] especially in the first year of life,[@bib15] can increase the risk of IBD development in childhood. We did not find that infections in the first 3 years of life were predictive of developing IBD, nor did we find that antibiotic usage in the first 10 years of life were predictive of an IBD diagnosis, although this latter analysis had a very limited sample size. It is unclear if the risk posed by infections in the first year of life is a manifestation of the infection itself per se or the use of antibiotics to treat the infections. We do not believe the risk posed by infections in the first year of life was secondary to persons with IBD being more likely to have an immunodeficiency disorder; disorders that can often present with an IBD-like picture.[@bib17] We did not find more immunodeficiency disorders diagnosed in our IBD cohort compared with controls. Hence, the first year of life is potentially a critical time for risk for IBD development.

How can these data be used in a practical sense to potentially impact on later IBD diagnosis? Limiting antibiotic usage in the management of routine infections could be desirable; however, it would be difficult to curb antibiotic use for many of the infections as serious as the ones we assessed. If it is increasingly accepted that antibiotics in the first year of life truly pose a risk for later chronic immune disease like IBD, then research is warranted to determine exactly what antibiotic intake does to infant gut microflora or intestinal or systemic immune responses. Interventions such as probiotic or prebiotic use could be considered after a course of antibiotics in children to prevent development of IBD or other chronic immune diseases.[@bib18]

It was particularly noteworthy that there were no differences among possible predictive factors for persons with IBD compared to their unaffected sibling controls. Those ultimately developing IBD compared to their unaffected siblings had similar neonatal events and similar events within the first of life in relation to infections and need for hospitalizations. As infection in the first year of life (and possibly the use of antibiotics to treat infection) is an important risk factor in our comparison of IBD cases with controls, it is uncertain why incidence of infection was not different for cases in comparison with sibling controls. Perhaps this suggests that because cases and siblings share genetics and environment, something unique must be occurring to cases that has not occurred to their unaffected siblings. Perhaps the genes not shared by the unaffected sibling include protective genes, which suggest a closer genetic evaluation of the differences between affected persons and their unaffected siblings may be fruitful. Secondly, while siblings share an environment and likely a similar diet while growing up, our findings suggest that there must be some environmental differences that we have not captured with our analyses. This may warrant a careful scrutiny of the diet and environment of unaffected siblings at the time of index case diagnosis. Some of those unaffected siblings may become affected over time, but many will not. The timing of the assessment of the unaffected siblings' environment and personal health attributes is critical.

No neonatal markers of health were found to be predictive of the eventual development of IBD. We have previously reported that neither undergoing birth by cesarean section[@bib13] nor being born to a mother who experienced antenatal or perinatal infections requiring antibiotics predicted later development of IBD.[@bib19] If delivery mode or maternal microbiota do influence the neonate's microbiota at a vulnerable time, or if other markers of neonatal ill health, as we explored in this study, have an impact on neonatal microbiome or immune system development,[@bib20], [@bib21] these changes seemingly can all be overcome. However, experiencing an infection in the first year of life was predictive of developing IBD, particularly under age 20 years.

Gastrointestinal illnesses in the first year of life, including abdominal pain, were not found to be associated with later development of IBD. This should be reassuring for parents who worry about whether their young children with infectious or noninfectious gastrointestinal illnesses would be at risk at developing IBD. We did not have enough instances of failure to thrive to fully assess whether it associated with the development of IBD.

Our study has a number of limitations. While we examined the most serious infections experienced by children in our hospital setting, we could not assess definitively which of the conditions were associated with antibiotic prescriptions. It is speculative whether the association of infections in the first year of life with ultimate diagnosis of IBD at all ages is actually related to antibiotic use. It is possible that there are other factors that are as or more important in the first year of life that may increase the risk for IBD, such as diet, or duration of or exclusivity of breastfeeding in the first year of life. Further, other environmental factors in the home, such as smoking, may contribute to the risk for IBD. It is also possible that for onset of IBD into late teenage years and adulthood, there are other factors that overwhelm any risk posed by early life events. However, we did find the strongest association between infection in the first year of life and childhood-onset IBD. In fact, our data support the likelihood that triggers for IBD arising in children may very well be different from triggers that ultimately lead to adult-onset IBD. Risk factors posed from the diet or an environmental factor, such as smoking, may occur well after the first year of life. Because not everyone exposed to infections (or antibiotics) in their first year of life develop IBD, it is also possible that variables such as protective dietary factors experienced later in childhood may protect against the potential risk posed by harmful infections or the antibiotics used to treat them.

However, key strengths of our study include that it is population-based, that we have assessed for all possible diagnoses associated with significant infectious and gastrointestinal illness that lead to early childhood hospitalizations, and that we have included sibling controls. No increased risk was posed by infections in the first year of life in cases of IBD compared to their siblings, yet the risk existed compared to controls. This suggests that other non-communal environmental factors may also be of importance in the pathogenesis of IBD. More research on exploring the childhood household environment in persons who develop IBD compared to those who do not is warranted.

In conclusion, our data suggest that having a mother with a diagnosis of IBD is the strongest predictor of developing IBD. Further, being in the highest socioeconomic quintile at birth, supporting the hygiene hypothesis,[@bib8] and having an infection within the first year of life increase the risk for developing IBD. Gastrointestinal illnesses, including abdominal pain, in the first year of life did not pose a risk for later development of IBD. Neonatal events that reflect infant health at birth did not predict later development of IBD. Together with our past reports that neither cesarean section birth nor antenatal or perinatal maternal use of antibiotics predict ultimate development of IBD, it seems that neonatal changes to the microbiome are subsumed by those occurring in the first year of life. Studies should explore the infant gut microbiome before and for several months after infections and/or antibiotic use to determine what changes occur that might promote the development of IBD later.

Supplementary Material {#appsec1}
======================

Supplementary Table 1Diagnoses Assessed for Association With Ultimate Development of Inflammatory Bowel DiseaseICD categoryICD-10-CMLabelICD-9-CMGradeAbdominal pain APR100Abdominal and pelvic pain789071 Asthma ASTHMAJ450Asthma493U ASTHMAJ4500Asthma493001 ASTHMAJ4501Asthma493011 ASTHMAJ451Asthma493U ASTHMAJ4510Asthma493101 ASTHMAJ4511Asthma493111 ASTHMAJ458Asthma493U ASTHMAJ4580Asthma493001 ASTHMAJ4581Asthma493011 ASTHMAJ459Asthma493U ASTHMAJ4590Asthma493901 ASTHMAJ4591Asthma493911Bone and muscle inflammation BONEIM6005Infective myositis, pelvic region and thigh72801 BONEIM6008Infective myositis, other72801 BONEIM8611Other acute osteomyelitis, shoulder region730011 BONEIM8612Other acute osteomyelitis, upper arm730021 BONEIM8616Other acute osteomyelitis, lower leg730061 BONEIM8617Other acute osteomyelitis, ankle and foot730071 BONEIM8618Other acute osteomyelitis, other site730081 BONEIM8625Subacute osteomyelitis, pelvic region and thigh730051 BONEIM8628Subacute osteomyelitis, other site730081 BONEIM8666Other chronic osteomyelitis, lower leg730161 BONEIM8667Other chronic osteomyelitis, ankle and foot730171 BONEIM8686Other osteomyelitis, lower leg730261 BONEIM8687Other osteomyelitis, ankle and foot730271 BONEIM8690Osteomyelitis, unspecified, multiple sites730292 BONEIM8692Osteomyelitis, unspecified, upper arm730222 BONEIM8693Osteomyelitis, unspecified, forearm730232 BONEIM8694Osteomyelitis, unspecified, hand730242 BONEIM8695Osteomyelitis, unspecified, pelvic region and thigh730252 BONEIM8696Osteomyelitis, unspecified, lower leg730262 BONEIM8697Osteomyelitis, unspecified, ankle and foot730272 BONEIM8698Osteomyelitis, unspecified, other site730282Cardiac infection CARDIB332Viral carditis429892Failure to thrive FTTR628Failure to thrive78342Fungal infections FUNIB350Tinea barbae and tinea capitis11001 FUNIB354Tinea corporis11051 FUNIB369Superficial mycosis, unspecified11191 FUNIB370Candidal stomatitis11201 FUNIB371Pulmonary candidiasis11241 FUNIB372Candidiasis of skin and nail11231 FUNIB374Candidiasis of other urogenital sites11221 FUNIB377Candidal sepsis11251 FUNIB3788Candidiasis of other sites112891 FUNIB379Candidiasis, unspecified11291 FUNIB402Pulmonary blastomycosis, unspecified11601 FUNIB408Other forms of blastomycosis11601 FUNIB409Blastomycosis, unspecified11601 FUNIB488Other specified mycoses11791 FUNIB49Unspecified mycosis11791Genitourinary GENITN10Acute tubulo-interstitial nephritis590102 GENITN309Cystitis, unspecified59591 GENITN4590Epididymitis604901 GENITN4591Orchitis604901 GENITN700Acute salpingitis and oophoritis61401 GENITN736Female pelvic peritoneal adhesions61461 GENITN760Acute vaginitis616101 GENITN762Acute vulvitis616101 GENITN764Abscess of vulva61641Gastrointestinal infections GIA010Typhoid fever0201 GIA013Paratyphoid fever C0231 GIA020*Salmonella enteritis*0301 GIA029Salmonella infection, unspecified0391 GIA031Shigellosis due to *Shigella flexneri*0411 GIA039Shigellosis, unspecified0491 GIA044Other intestinal *Escherichia coli* infections8092 GIA045Campylobacter enteritis8431 GIA047Enterocolitis due to *Clostridium difficile*8451 GIA048Other specified bacterial intestinal infections8492 GIA049Bacterial intestinal infection, unspecified0851 GIA06Diarrhea (Amebic)060U GIA060Diarrhea (Amebic)0601 GIA061Diarrhea (Amebic)0611 GIA062Diarrhea (Amebic)0621 GIA063Diarrhea (Amebic)0681 GIA064Diarrhea (Amebic)0631 GIA065Diarrhea (Amebic)0641 GIA066Diarrhea (Amebic)0651 GIA067Diarrhea (Amebic)0661 GIA068Diarrhea (Amebic)0681 GIA069Diarrhea (Amebic)0691 GIA071Giardiasis \[lambliasis\]0711 GIA079Diarrhea (Protozoal)0791 GIA080Rotaviral enteritis8611 GIA081Acute gastroenteropathy due to Norwalk agent8632 GIA082Adenoviral enteritis8621 GIA083Other viral enteritis8692 GIA084Viral intestinal infection, unspecified0881 GIA09Diarrhea and gastroenteritis of presumed infection0932 GIA090Other and unspecified gastroenteritis and colitis5589U GIA099Gastroenteritis and colitis of unspecified origin5589U GIP783Diarrhea neonatal (transient)77782 GIR11Vomiting7870U GIR110Vomiting787031 GIR111Vomiting787021 GIR112Vomiting787031 GIR113Vomiting787011Gastrointestinal disease GIDK120Recurrent oral aphthae52821 GIDK121Other forms of stomatitis52802 GIDK122Cellulitis and abscess of mouth52832 GIDK123Oral mucositis (ulcerative)52801U GIDK20Oesophagitis530102 GIDK210Gastro-oesophageal reflux disease with esophagitis530111 GIDK219Gastro-oesophageal reflux disease without esophagitis530811 GIDK222Oesophageal obstruction53031 GIDK228Other specified diseases of oesophagus530892 GIDK254Gastric ulcer, chronic or unspecified with hemorrhage531402 GIDK290Acute haemorrhagic gastritis535011 GIDK291Other acute gastritis535001 GIDK295Chronic gastritis, unspecified535102 GIDK296Other gastritis535402 GIDK297Gastritis, unspecified535502 GIDK298Duodenitis535602 GIDK350Acute appendicitis with generalized peritonitis54001 GIDK351Acute appendicitis with peritoneal abscess54011 GIDK352Acute appendicitis with generalized peritonitis5400U GIDK353Acute appendicitis with localized peritonitis5401U GIDK358Acute appendicitis, other and unspecified5409U GIDK359Acute appendicitis, unspecified54091 GIDK650Acute peritonitis56721 GIDK658Other peritonitis56782 GIDK659Peritonitis, unspecified56791Hepatitis HEPB179Acute viral hepatitis, unspecified5733U HEPB181Chronic viral hepatitis B without delta-agent70321 HEPB189Chronic viral hepatitis, unspecified7091 HEPB199Unspecified viral hepatitis without hepatic coma7091 HEPK754Autoimmune hepatitis57331 HEPK758Other specified inflammatory liver diseases57332 HEPK759Inflammatory liver disease, unspecified57331Herpes virus HVB000Eczema herpeticum5401 HVB001Herpes viral vesicular dermatitis54792 HVB002Herpes viral gingivitis and pharyngotonsilitis5422 HVB004Herpes viral encephalitis5431 HVB005Herpes viral ocular disease54402 HVB007Disseminated herpesviral disease5451 HVB008Other forms of herpesviral infection5462 HVB009Herpesviral infection, unspecified5491 HVB010Varicella meningitis5272 HVB011Varicella encephalitis5201 HVB012Varicella pneumonia5211 HVB018Varicella with other complications5272 HVB019Varicella without complication5291 HVB023Zoster ocular disease53202Intracranial infections IIA321Listerial meningitis and meningoencephalitis2701 IIA390Meningococcal meningitis3601 IIA858Other specified viral encephalitis4981 IIA86Unspecified viral encephalitis4991 IIA870Enteroviral meningitis4792 IIA871Adenoviral meningitis4911 IIA872Lymphocytic choriomeningitis4901 IIA879Viral meningitis, unspecified4791 IIB941Sequelae of viral encephalitis13901 IIG000Haemophilus meningitis32001 IIG001Pneumococcal meningitis32011 IIG002Streptococcal meningitis32021 IIG003Staphylococcal meningitis32031 IIG008Other bacterial meningitis320892 IIG009Bacterial meningitis, unspecified32091 IIG01Meningitis in bacterial diseases classified elsewhere32072 IIG020Meningitis in viral diseases classified elsewhere32121 IIG030Nonpyogenic meningitis32201 IIG038Meningitis due to other specified causes32292 IIG039Meningitis, unspecified32291 IIG040Acute disseminated encephalitis32352 IIG042Bacterial meningoencephalitis and meningomyelitis,32091 IIG048Other encephalitis, myelitis and encephalomyelitis32381 IIG049Encephalitis, myelitis and encephalomyelitis, unspecified32391 IIG050Encephalitis, myelitis and encephalomyelitis in ba32341 IIG051Encephalitis, myelitis and encephalomyelitis32301 IIG060Intracranial abscess and granuloma32401 IIG061Intraspinal abscess and granuloma32411 IIG062Extradural and subdural abscess, unspecified32491 IIG08Intracranial and intraspinal phlebitis and thrombosis3251Lymphadenitis LYMPHL040Acute lymphadenitis of face, head and neck6831 LYMPHL041Acute lymphadenitis of trunk6831 LYMPHL042Acute lymphadenitis of upper limb6831 LYMPHL043Acute lymphadenitis of lower limb6831 LYMPHL048Acute lymphadenitis of other sites6831Newborn infections NEWIP027Fetus and newborn affected by chorioamnionitis76271 NEWIP360Sepsis of newborn due to streptococcus, group B77181 NEWIP361Sepsis of newborn due to other and unspecified streptococcus77181 NEWIP362Sepsis of newborn due to Staphylococcus aureus77181 NEWIP363Sepsis of newborn due to other and unspecified staphylococcus77181 NEWIP364Sepsis of newborn due to Escherichia coli77181 NEWIP368Other bacterial sepsis of newborn77181 NEWIP369Bacterial sepsis of newborn, unspecified77181 NEWIP38Omphalitis of newborn with or without mild hemorrhage77141 NEWIP390Neonatal infective mastitis77151 NEWIP391Neonatal conjunctivitis and dacryocystitis77161 NEWIP393Neonatal urinary tract infection77181 NEWIP394Neonatal skin infection77182 NEWIP398Other specified infections specific to the perinatal period77181 NEWIP77Necrotizing enterocolitis of fetus and newborn77751Ocular infections OIB303Acute epidemic haemorrhagic conjunctivitis7741 OIB309Viral conjunctivitis, unspecified77991Oral, pharyngeal sinus infections OPSIB084Enteroviral vesicular stomatitis with exanthem7431 OPSIB085Enteroviral vesicular pharyngitis7401 OPSIB250Cytomegaloviral pneumonitis7851 OPSIB251Cytomegaloviral hepatitis7851 OPSIB258Other cytomegaloviral diseases7851 OPSIB259Cytomegaloviral disease, unspecified7851 OPSIB270Gammaherpesviral mononucleosis0751 OPSIB279Infectious mononucleosis, unspecified0751 OPSIJ00Acute nasopharyngitis \[common cold\]4601 OPSIJ010Acute maxillary sinusitis46101 OPSIJ012Acute ethmoidal sinusitis46121 OPSIJ013Acute sphenoidal sinusitis46131 OPSIJ019Acute sinusitis, unspecified46191 OPSIJ020Streptococcal pharyngitis3401 OPSIJ028Acute pharyngitis due to other specified organisms4621 OPSIJ029Acute pharyngitis, unspecified4621 OPSIJ030Streptococcal tonsillitis3401 OPSIJ039Acute tonsillitis, unspecified4631 OPSIJ040Acute laryngitis46401 OPSIJ041Acute tracheitis464101 OPSIJ050Acute obstructive laryngitis \[croup\]46441 OPSIJ051Acute epiglottitis464301Otitis media OTITH65Nonsuportive otitis media^∗^unknownU OTITH650Nonsuportive otitis media^∗^381011 OTITH651Nonsuportive otitis media^∗^381002 OTITH652Nonsuportive otitis media^∗^381102 OTITH653Nonsuportive otitis media^∗^381202 OTITH654Nonsuportive otitis media^∗^38131 OTITH659Nonsuportive otitis media^∗^38141 OTITH66Otitis media^∗^unknownU OTITH660Otitis media^∗^382002 OTITH661Otitis media^∗^38211 OTITH662Otitis media^∗^38221 OTITH663Otitis media^∗^38231 OTITH664Otitis media^∗^38241 OTITH669Otitis media^∗^38291 OTITH67Otitis media class elsewhere^∗^UNKU OTITH670Otitis media class elsewhere^∗^382023 OTITH671Otitis media class elsewhere^∗^382021 OTITH678Otitis media class elsewhere^∗^382023Pancreatitis PANCK85Acute pancreatitis5770U PANCK850Idiopathic acute pancreatitis57702 PANCK851Biliary acute pancreatitis57702 PANCK858Other acute pancreatitis57702 PANCK859Acute pancreatitis, unspecified57702Parasitic infections PARIB508Other severe and complicated *Plasmodium falciparum*8401 PARIB509Plasmodium falciparum malaria, unspecified8401 PARIB519Plasmodium vivax malaria without complication8411 PARIB54Unspecified malaria8461 PARIB588Toxoplasmosis with other organ involvement13072 PARIB589Toxoplasmosis, unspecified13091 PARIB829Intestinal parasitism, unspecified1291 PARIB830Visceral larva migrans12801 PARIB850Pediculosis due to *Pediculus humanus capitis*13201 PARIB851Pediculosis due to *Pediculus humanus corporis*13211 PARIB852Pediculosis, unspecified13291 PARIB86Scabies13301 PARIB878Myiasis of other sites13401 PARIB89Unspecified parasitic disease13691Pulmonary infections (bacterial) PIA1501Tuberculosis of lung, confirmed by sputum microscopy11932 PIA151Tuberculosis of lung, confirmed by culture only11942 PIA1531Tuberculosis of lung, confirmed by unspecified measures11901 PIA157Primary respiratory tuberculosis, confirmed bacteriology10902 PIA1611Tuberculosis of lung, bacteriological and histological confirmation11911 PIA162Tuberculosis of lung, without mention of bacteriological and histological confirmation119U PIA1621Tuberculosis of lung, without mention of bacteriol11962 PIA167Primary respiratory tuberculosis11962 PIA169Respiratory tuberculosis unspecified119U PIA1690Respiratory tuberculosis unspecified11962 PIA170Tuberculous meningitis13002 PIA178Other tuberculosis of nervous system13802 PIA182Tuberculous peripheral lymphadenopathy17202 PIA370Whooping cough due to Bordetella pertussis3301 PIA371Whooping cough due to Bordetella parapertussis3311 PIA379Whooping cough, unspecified3391 PIJ068Other acute upper respiratory infections46581 PIJ069Acute upper respiratory infection, unspecified46591 PIJ13Pneumonia due to *Streptococcus pneumoniae*4812 PIJ14Pneumonia due to *Haemophilus influenzae*48221 PIJ150Pneumonia due to *Klebsiella pneumoniae*48201 PIJ151Pneumonia due to Pseudomonas48211 PIJ152Pneumonia due to Staphylococcus482401 PIJ153Pneumonia due to Streptococcus, group B482321 PIJ154Pneumonia due to other streptococci482392 PIJ156Pneumonia due to other Gram-negative bacteria482831 PIJ157Pneumonia due to *Mycoplasma pneumoniae*48301 PIJ158Other bacterial pneumonia482891 PIJ159Bacterial pneumonia, unspecified48291 PIJ170Pneumonia in bacterial diseases classified elsewhere48482 PIJ171Pneumonia in viral diseases classified elsewhere48482 PIJ18Bronchopneumonia481U PIJ180Bronchopneumonia, unspecified4851 PIJ181Lobar pneumonia, unspecified4811 PIJ182Bronchopneumonia5141 PIJ188Bronchopneumonia4861 PIJ189Pneumonia, unspecified4861 PIJ20Acute bronchitis4660U PIJ200Acute bronchitis46601 PIJ201Acute bronchitis46601 PIJ202Acute bronchitis46601 PIJ203Acute bronchitis46601 PIJ204Acute bronchitis46601 PIJ205Acute bronchitis46601 PIJ206Acute bronchitis46601 PIJ207Acute bronchitis46601 PIJ310Chronic rhinitis47201 PIJ312Chronic pharyngitis47211 PIJ320Chronic maxillary sinusitis47301 PIJ322Chronic ethmoidal sinusitis47321 PIJ329Chronic sinusitis, unspecified47391 PIJ47Bronchiectasis4941 PIR05Cough78621Systemic bacterial infections, primary site not specified SBNOSA191Acute miliary tuberculosis of multiple sites18002 SBNOSA199Miliary tuberculosis, unspecified18902 SBNOSA400Sepsis due to streptococcus, group A3801 SBNOSA401Sepsis due to streptococcus, group B3801 SBNOSA403Sepsis due to *Streptococcus pneumoniae*3821 SBNOSA408Other streptococcal sepsis3801 SBNOSA409Streptococcal sepsis, unspecified3801 SBNOSA410Sepsis due to *Staphylococcus aureus*38101 SBNOSA411Sepsis due to other specified staphylococcus38191 SBNOSA412Sepsis due to unspecified staphylococcus38101 SBNOSA413Sepsis due to *Haemophilus influenzae*38411 SBNOSA4150Sepsis due to *Escherichia coli* \[*E coli*\]38421 SBNOSA4151Sepsis due to *Pseudomonas*38431 SBNOSA4158Sepsis due to other Gram-negative organisms38491 SBNOSA4180Sepsis due to *Enterococcus*3881 SBNOSA4188Other specified sepsis3881 SBNOSA419Sepsis, unspecified3891 SBNOSA490Staphylococcal infection, unspecified site41111 SBNOSA491Streptococcal infection, unspecified site41091 SBNOSA492*Haemophilus influenzae* infection, unspecified site4151 SBNOSA498Other bacterial infections of unspecified site41891 SBNOSA499Bacterial infection, unspecified4191 SBNOSA689Relapsing fever, unspecified8791 SBNOSB948Sequelae of other specified infectious and parasites13981 SBNOSB950Streptococcus, group A, as the cause of diseases41011 SBNOSB956*Staphylococcus aureus* as the cause of diseases41111 SBNOSB961*Klebsiella pneumoniae* \[*K pneumoniae*\] as the cause4131 SBNOSB962*Escherichia coli* \[E coli\] as the cause of disease4141 SBNOSB963*Haemophilus influenzae* \[*H influenzae*\] as the cause4151 SBNOSB9680*Helicobacter pylori* \[*H pylori*\] as the cause of disease41861 SBNOSB9681Enterococcus as the cause of diseases classified41041 SBNOSB9688Other specified bacterial agents as the cause of disease41891Respiratory infections (viral) RIJ09Influenza due to certain identified influenza virus48781 RIJ100Influenza with pneumonia, other influenza virus identified48701 RIJ101Influenza with other respiratory manifestations48711 RIJ108Influenza with other manifestations48781 RIJ110Influenza with pneumonia, virus not identified48701 RIJ111Influenza with other respiratory manifestations48711 RIJ118Influenza with other manifestations, virus not identified48781 RIJ120Adenoviral pneumonia48001 RIJ121Respiratory syncytial virus pneumonia48011 RIJ122Parainfluenza virus pneumonia48021 RIJ123Human metapneumovirus pneumonia4808U RIJ128Other viral pneumonia48081 RIJ129Viral pneumonia, unspecified48091 RIJ40Bronchitis, not specified4901 RIJ41Simple and mucopurulent chronic bronchitis4911U RIJ410Simple and mucopurulent chronic bronchitis49101 RIJ411Simple and mucopurulent chronic bronchitis49111 RIJ418Simple and mucopurulent chronic bronchitis49182 RIJ42Unspecified chronic bronchitis49191Skin infection SIA281Cat-scratch disease7831 SIA46Erysipelas351 SIB081Molluscum contagiosum7801 SIL00Staphylococcal scalded skin syndrome695812 SIL010Impetigo \[any organism\] \[any site\]6841 SIL011Impetiginization of other dermatoses6841 SIL020Cutaneous abscess, furuncle and carbuncle of face68001 SIL021Cutaneous abscess, furuncle and carbuncle of neck68011 SIL022Cutaneous abscess, furuncle and carbuncle of trunk68021 SIL023Cutaneous abscess, furuncle and carbuncle of buttock68051 SIL024Cutaneous abscess, furuncle and carbuncle of limb68031 SIL028Cutaneous abscess, furuncle and carbuncle of other68081 SIL0300Cellulitis of finger681001 SIL0301Cellulitis of toe681101 SIL0310Cellulitis of upper limb68231 SIL0311Cellulitis of lower limb68261 SIL032Cellulitis of face68201 SIL0330Cellulitis of chest wall68221 SIL0331Cellulitis of abdominal wall68221 SIL0332Cellulitis of umbilicus68221 SIL0333Cellulitis of groin68221 SIL0334Cellulitis of back \[any part except buttock\]68221 SIL0335Cellulitis of buttock68251 SIL0336Cellulitis of perineum68221 SIL0339Cellulitis of trunk, unspecified68221 SIL038Cellulitis of other sites68282 SIL039Cellulitis, unspecified68291 SIL050Pilonidal cyst with abscess68501 SIL059Pilonidal cyst without abscess68511 SIL080Pyoderma686091 SIL088Other specified local infections of skin and subcutaneous tissue68681 SIL089Local infection of skin and subcutaneous tissue68691Congenital infection STI-related infection STIA630Anogenital (venereal) warts78191 STIA749Chlamydial infection, unspecified78882 STIA500Early congenital syphilis, symptomatic9002 CONIA509Congenital syphilis, unspecified9091Systemic viral infection primary site not specified SVNOSB088Other specified viral infections characterized by78892 SVNOSB09Unspecified viral infection characterized by skin5792 SVNOSB340Adenovirus infection, unspecified site7901 SVNOSB341Enterovirus infection, unspecified site78892 SVNOSB348Other viral infections of unspecified site79891 SVNOSB349Viral infection, unspecified79992 SVNOSB970Adenovirus as the cause of diseases7901 SVNOSB971Enterovirus as the cause of diseases79892 SVNOSB972Coronavirus as the cause of diseases79892 SVNOSB974Respiratory syncytial virus as the cause of disease7961 SVNOSB9780Parainfluenza virus as the cause of diseases79892 SVNOSB9788Other viral agents as the cause of diseases classified79891Miscellaneous MISA227Anthrax sepsis2231 MISA312Disseminated mycobacterium avium-intracellulare3121 MISA319Mycobacterial infection, unspecified3191 MeningococcusA398Other meningococcal infections36892 MISA829Rabies, unspecified0711[^13]Supplementary Table 2Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Crohn's Disease, Under Age 10 Years Among All Persons With Crohn's Disease Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs no3.150.70, 14.14.13Socioeconomic status Q1Q2 vs Q12.210.79, 6.17.13 Q2Q3 vs Q11.160.38, 3.54.79 Q3Q4 vs Q11.640.53, 5.08.39 Q4Q5 vs Q11.690.49, 5.83.40Geographyrural vs urban3.031.17, 7.84.02Apgar 1 min7+ vs \<71.220.50, 2.97.66Gestational age---0.910.75, 1.11.35Birth weight---1.0001.000, 1.001.46Readmitted in year 1No vs yes1.120.46, 2.75.80Cesarean sectionYes vs no0.480.19, 1.21.12Maternal IBDYes vs no9.221.80, 47.32.01[^14]Supplementary Table 3Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Ulcerative Colitis, Under Age 10 Years Among All Persons With Ulcerative Colitis Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs no2.710.60, 12.20.19 Q2Q2 vs Q11.630.49, 5.41.42 Q3Q3 vs Q11.970.58, 6.66.28 Q4Q4 vs Q11.970.58, 6.62.28 Q5Q5 vs Q11.100.30, 4.07.89GeographyRural vs urban1.830.58, 5.77.30Apgar 1 min7+ vs \<70.440.16, 1.21.11Gestational age---0.980.76, 1.26.88Birth weight---1.0001.000, 1.001.28Readmitted in year 1No vs yes0.750.30, 1.83.52Cesarean sectionYes vs no1.450.52, 4.06.48Maternal IBDYes vs no3.130.31, 31.89.34[^15]Supplementary Table 4Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Crohn's Disease, Under Age 20 Years Among All Persons With Crohn's Disease Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs no1.701.12, 2.59.01Socioeconomic status Q2Q2 vs Q11.260.87, 1.84.22 Q3Q3 vs Q10.890.59, 1.35.59 Q4Q4 vs Q11.360.92, 2.01.12 Q5Q5 vs Q11.330.86, 2.06.19Geographyrural vs urban0.900.62, 1.32.59Apgar 1 min7+ vs \<71.380.95, 2.01.09ICU admissionNo vs yes1.070.53, 2.17.85Gestational age---1.040.96, 1.13.35Birth weight---1.0001.000, 1.000.38Readmitted in year 1No vs yes1.140.77, 1.71.50Cesarean sectionYes vs no1.050.76, 1.47.76Maternal IBDYes vs no7.074.10, 12.22\<.001Hospitalization for GIYes vs no0.630.21, 1.91.42[^16]Supplementary Table 5Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Ulcerative Colitis, Under Age 20 Years Among All Persons With Ulcerative Colitis Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueInfection year 1Yes vs no1.480.90, 2.44.12Socioeconomic status Q2Q2 vs Q11.771.11, 2.82.02 Q3Q3 vs Q11.470.90, 2.38.12 Q4Q4 vs Q11.380.84, 2.27.19 Q5Q5 vs Q11.530.90, 2.61.12GeographyRural vs urban1.050.67, 1.64.84Apgar 1 min7+ vs \<70.770.51, 1.16.21ICU admissionNo vs yes1.200.39, 3.68.75Gestational age---0.990.89, 1.09.75Birth weight---1.0001.000, 1.000.56Readmitted in year 1No vs yes1.090.68, 1.72.73Cesarean sectionYes vs no1.240.86, 1.78.25Maternal IBDYes vs no2.451.07, 5.61.03Hospitalization for GIYes vs no0.570.20, 1.59.28[^17]Supplementary Table 6Association Between Demographic Variables at Birth and Clinical Events in the First Year of Life (Infections Excluding Viral Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Inflammatory Bowel Disease, at Any Age Among All Persons With Inflammatory Bowel Disease Compared With ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueBacterial infect onlyYes vs no1.100.94, 1.30.24 Q1NF vs Q10.750.36, 1.54.43 Q2Q2 vs Q11.311.02, 1.68.04 Q3Q3 vs Q11.090.84, 1.42.51 Q4Q4 vs Q11.371.06, 1.77.02 Q5Q5 vs Q11.351.01, 1.79.04GeographyRural vs urban0.910.72, 1.15.43Apgar 1 min7+ vs \<71.100.87, 1.39.44Apgar 5 min7+ vs \<71.060.49, 2.31.88ICU admissionNo vs yes1.070.64, 1.79.79Gestational age---1.0020.95, 1.06.93Birth weight---1.0001.000, 1.000.82Readmitted in year 1No vs yes1.200.93, 1.54.16Cesarean sectionYes vs no1.060.86, 1.32.58Maternal IBDYes vs no4.573.11, 6.73\<.001Hospitalization for GIYes vs no0.780.45, 1.35.38[^18]Supplementary Table 7Association Between Demographic Variables at Birth and Clinical Events in the First 3 Years of Life (Infections, Gastrointestinal Illnesses, Failure to Thrive, and Hospital Readmission) and the Development of Inflammatory Bowel Disease, at Any Age Among All Persons With Inflammatory Bowel Disease Compared to ControlsEffectComparisonOR estimate95% Wald confidence limits*P* valueInfection in first 3 yYes vs no1.260.77, 2.06.35Socioeconomic status Q1NF vs Q10.760.37, 1.56.45 Q2Q2 vs Q11.311.02, 1.68.04 Q3Q3 vs Q11.090.84, 1.42.51 Q4Q4 vs Q11.361.05, 1.76.02 Q5Q5 vs Q11.351.01, 1.79.04GeographyRural vs urban0.910.72, 1.15.44Apgar 1 min7+ vs \<71.110.88, 1.40.39Apgar 5 min7+ vs \<71.090.50, 2.36.83ICU admissionNo vs yes0.890.55, 1.46.65Gestational age---1.010.96, 1.06.82Birth weight---1.0001.000, 1.000.8Readmitted in year 1No vs yes1.180.92, 1.51.20Cesarean sectionYes vs no1.060.86, 1.32.58Maternal IBDYes vs no4.603.13, 6.77\<.001Hospitalization for GIYes vs no0.770.50, 1.17.22[^19]
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[^1]: ICU, intensive care unit; NF, not found; Q, quintile.

[^2]: Data in case and control columns reflect % in each category unless otherwise specified.

[^3]: Data for % with Apgar of 7+.

[^4]: Data reflects grams.

[^5]: ICU, intensive care unit; NF, not found; Q, quintile.

[^6]: Hospitalized for GI means hospitalized for any of gastrointestinal infections, gastrointestinal disease, or abdominal pain in the first year of life.

[^7]: ICU, intensive care unit; NF, not found; Q, quintile.

[^8]: Hospitalized for GI means hospitalized for any of gastrointestinal infections, gastrointestinal disease or abdominal pain in the first year of life.

[^9]: ICU, intensive care unit; Q, quintile.

[^10]: GI, gastrointestinal; ICU, intensive care unit; Q, quintile.

[^11]: NF, not found; Q, quintile.

[^12]: Age at diagnosis of IBD case compared to age of sibling at time of diagnosis.

[^13]: BONEI, bone inflammation; CARDI, cardiac inflammation; FUNI, fungal infection; GENIT, genitourinary; GI, Gastrointestinal infections; GID, gastrointestinal disease.

[^14]: Q, quintile.

[^15]: Q, quintile.

[^16]: GI, gastrointestinal; ICU, intensive care unit; Q, quintile.

[^17]: GI, gastrointestinal; ICU, intensive care unit; Q, quintile.

[^18]: GI, gastrointestinal; ICU, intensive care unit; Q, quintile.

[^19]: GI, gastrointestinal; ICU, intensive care unit; Q, quintile.
